Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats

S. Hossein Fatemi; Timothy D. Folsom; Teri J. Reutiman; Twinkle Pandian; Natalie N. Braun; Kari Haug

doi:10.1016/j.schres.2008.05.016

Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats

S. Hossein Fatemi, Timothy D. Folsom, Teri J. Reutiman, Twinkle Pandian, Natalie N. Braun, Kari Haug

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.

Original language	English
Pages (from-to)	127-134
Number of pages	8
Journal	Schizophrenia research
Volume	104
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2008.05.016
State	Published - Sep 2008

Keywords

Autism
Connexin 43
GFAP
Prefrontal cortex
Rat
Schizophrenia

Access to Document

10.1016/j.schres.2008.05.016

Cite this

@article{c44764451b3c49a69b8a3812d53ff088,

title = "Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats",

abstract = "Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.",

keywords = "Autism, Connexin 43, GFAP, Prefrontal cortex, Rat, Schizophrenia",

author = "Fatemi, {S. Hossein} and Folsom, {Timothy D.} and Reutiman, {Teri J.} and Twinkle Pandian and Braun, {Natalie N.} and Kari Haug",

note = "Funding Information: Funding for this study was provided by Stanley Medical Research Institute grant 02R-232. The funding source had no further role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: Grant support by Stanley Medical Research Institute (02R-232) to SHF is acknowledged. Additionally, we would like to acknowledge the kind gift of olanzapine from Eli Lilly and Company and provided by Dr. L. Jaton. We wish to thank L. Iversen for secretarial assistance.",

year = "2008",

month = sep,

doi = "10.1016/j.schres.2008.05.016",

language = "English",

volume = "104",

pages = "127--134",

journal = "Schizophrenia research",

issn = "0920-9964",

number = "1-3",

}

TY - JOUR

T1 - Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats

AU - Fatemi, S. Hossein

AU - Folsom, Timothy D.

AU - Reutiman, Teri J.

AU - Pandian, Twinkle

AU - Braun, Natalie N.

AU - Haug, Kari

N1 - Funding Information: Funding for this study was provided by Stanley Medical Research Institute grant 02R-232. The funding source had no further role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: Grant support by Stanley Medical Research Institute (02R-232) to SHF is acknowledged. Additionally, we would like to acknowledge the kind gift of olanzapine from Eli Lilly and Company and provided by Dr. L. Jaton. We wish to thank L. Iversen for secretarial assistance.

PY - 2008/9

Y1 - 2008/9

N2 - Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.

AB - Astrocytic markers glial fibrillary acidic protein (GFAP) and connexin 43 (CX43) are known to have altered expression in brains of subjects with psychiatric disorders including autism and major depression. The current study investigated whether GFAP and CX43 expressions are affected by several commonly used psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid). Using SDS-PAGE and western blotting technique, we observed that CX43 protein expression in prefrontal cortex was significantly increased following chronic treatment with fluoxetine and clozapine, while it was significantly decreased by haloperidol and lithium. GFAP protein expression was significantly decreased following chronic treatment with clozapine and valproic acid. These results suggest that astroglial markers GFAP and CX43 could be potential targets for therapeutic intervention.

KW - Autism

KW - Connexin 43

KW - GFAP

KW - Prefrontal cortex

KW - Rat

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=50249181082&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.05.016

DO - 10.1016/j.schres.2008.05.016

M3 - Article

C2 - 18585900

AN - SCOPUS:50249181082

SN - 0920-9964

VL - 104

SP - 127

EP - 134

JO - Schizophrenia research

JF - Schizophrenia research

IS - 1-3

ER -

Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this